Nykredit A S Purchases Shares of 79,697 The Cooper Companies, Inc. $COO

Key Points

• Nykredit A/S purchased 79,697 shares of Cooper Companies worth approximately $5.7 million in the second quarter. Other major investors, including BlackRock and Generation Investment Management, also established sizable positions.
• Analyst sentiment remains mixed: five analysts rate the stock a Buy, 12 rate it Hold, and two rate it Sell. The consensus rating is Hold, with an average price target of $71.47.
• Cooper Companies beat quarterly EPS estimates, announced a $3 billion share-repurchase authorization, and reported recent insider buying totaling 34,701 shares. Shares opened at $54.12, near the company’s 12-month low.

Nykredit A S purchased a new position in The Cooper Companies, Inc. (NASDAQ:COO - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 79,697 shares of the medical device company's stock, valued at approximately $5,715,000.

A number of other large investors also recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Cooper Companies in the 2nd quarter valued at $1,077,762,000. Generation Investment Management LLP purchased a new stake in shares of Cooper Companies in the second quarter valued at approximately $356,304,000. Jupiter Topco LLC acquired a new position in shares of Cooper Companies during the 2nd quarter worth $305,074,000. Franklin Resources Inc. increased its stake in Cooper Companies by 108.2% in the 4th quarter. Franklin Resources Inc. now owns 4,022,033 shares of the medical device company's stock valued at $329,646,000 after purchasing an additional 2,089,763 shares in the last quarter. Finally, JANA Partners Management LP raised its stake in shares of Cooper Companies by 0.5% during the 2nd quarter. JANA Partners Management LP now owns 3,582,480 shares of the medical device company's stock worth $256,900,000 after buying an additional 17,322 shares during the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on COO shares. Robert W. Baird set a $61.00 target price on Cooper Companies and gave the company a "neutral" rating in a report on Thursday, September 10th. Bank of America reaffirmed a "neutral" rating and issued a $65.00 price objective (down from $80.00) on shares of Cooper Companies in a report on Thursday, September 10th. Zacks Research lowered Cooper Companies from a "hold" rating to a "strong sell" rating in a research report on Friday, September 11th. Mizuho set a $75.00 price objective on Cooper Companies and gave the stock an "outperform" rating in a report on Thursday, September 10th. Finally, Citigroup reiterated a "neutral" rating and issued a $60.00 price objective (down from $80.00) on shares of Cooper Companies in a report on Thursday, September 10th. Five investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $71.47.

Cooper Companies Trading Down 2.1%

Shares of NASDAQ:COO opened at $54.12 on Tuesday. The Cooper Companies, Inc. has a 12-month low of $51.01 and a 12-month high of $89.83. The firm has a fifty day moving average of $69.58 and a two-hundred day moving average of $68.36. The company has a quick ratio of 0.73, a current ratio of 1.22 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $10.29 billion, a P/E ratio of 18.47, a price-to-earnings-growth ratio of 2.25 and a beta of 0.82.

Cooper Companies (NASDAQ:COO - Get Free Report) last announced its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.03. The business had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.10 billion. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The firm's revenue was up .5% on a year-over-year basis. During the same period in the previous year, the company earned $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, equities analysts expect that The Cooper Companies, Inc. will post 4.53 EPS for the current fiscal year.

Cooper Companies declared that its board has initiated a share buyback plan on Wednesday, September 9th that allows the company to repurchase $3.00 billion in shares. This repurchase authorization allows the medical device company to purchase up to 22.7% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's leadership believes its stock is undervalued.

Insider Buying and Selling

In related news, Director Lawrence Kurzius bought 10,000 shares of the business's stock in a transaction that occurred on Monday, September 14th. The stock was purchased at an average cost of $53.91 per share, for a total transaction of $539,100.00. Following the purchase, the director directly owned 21,099 shares in the company, valued at $1,137,447.09. This trade represents a 90.10% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Paul Keel acquired 4,701 shares of Cooper Companies stock in a transaction on Friday, September 11th. The stock was purchased at an average price of $53.18 per share, with a total value of $249,999.18. Following the transaction, the director directly owned 4,701 shares in the company, valued at approximately $249,999.18. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have purchased 34,701 shares of company stock valued at $1,880,039. 2.08% of the stock is owned by company insiders.

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.